Literature DB >> 8652840

Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.

J Brisco1, E Hughes, S H Neoh, P J Sykes, K Bradstock, A Enno, J Szer, K McCaul, A A Morley.   

Abstract

In children with acute lymphoblastic leukemia (ALL), the level of minimal residual disease (MRD) at the end of induction strongly predicts outcome, presumably because it measures both drug sensitivity and the number of leukemic cells requiring elimination. Children with high levels (> 10(-3) leukemic cells per marrow cell) nearly always relapse, whereas those with low levels (<2 x 10(-5)) seldom do. However, the importance of MRD in adult ALL is unclear. We studied 27 patients aged 14 to 74 who were treated with a standard protocol and who attained morphological remission. MRD in the marrow at first remission was quantified by using the polymerase chain reaction (PCR), with the rearranged immunoglobulin heavy chain gene as a molecular marker. Levels of MRD varied from 3 x 10(-1) to <7 x 10(-7). The probability of long-term relapse-free survival was significantly related to the level of MRD and only one of nine patients with MRD >10(-3) did not relapse. For patients who did relapse, there was an inverse relationship between MRD level and the length of remission. Overall, MRD in adults in whom a translocation had not been identified was significantly higher than in comparably-treated children, suggesting that ALL in adults is more drug-resistant than in children.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8652840

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Establishment and study of different real-time polymerase chain reaction assays for the quantification of cells with deletions of chromosome 7.

Authors:  Elia Mattarucchi; Milena Marsoni; Alberto Passi; Francesco Lo Curto; Francesco Pasquali; Giovanni Porta
Journal:  J Mol Diagn       Date:  2006-05       Impact factor: 5.568

2.  Clinical trials report. Minimal residual disease quantification in adult acute lymphoblastic leukemia.

Authors:  Heather Landau; Mark A Weiss
Journal:  Curr Oncol Rep       Date:  2006-09       Impact factor: 5.075

Review 3.  Environment-mediated drug resistance: a major contributor to minimal residual disease.

Authors:  Mark B Meads; Robert A Gatenby; William S Dalton
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

4.  Outcome predictors after retransplantation in relapsed acute lymphoblastic leukemia: a multicenter, retrospective study.

Authors:  Yasuo Mori; Kensuke Sasaki; Yoshikiyo Ito; Takuro Kuriyama; Toshiyuki Ueno; Masanori Kadowaki; Takatoshi Aoki; Takeshi Sugio; Goichi Yoshimoto; Koji Kato; Takahiro Maeda; Koji Nagafuji; Koichi Akashi; Toshihiro Miyamoto
Journal:  Ann Hematol       Date:  2020-11-05       Impact factor: 3.673

5.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

Review 6.  Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy.

Authors:  Renato Bassan; Orietta Spinelli
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

7.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

Review 8.  Childhood acute myeloid leukaemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

Review 9.  Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Masamitsu Yanada; Ryuzo Ohno; Tomoki Naoe
Journal:  Int J Hematol       Date:  2008-12-18       Impact factor: 2.490

Review 10.  Immunologic monitoring in adults with acute lymphoblastic leukemia.

Authors:  María-Belén Vidriales; Alberto Orfao; Jesús F San-Miguel
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.